Abstract Objective To investigate the immunological mechanism of prednisone in the treatment of infantile spasm (IS) by evaluating the immune function of IS children before and after treatment. Methods Thirty children with IS were enrolled as IS group. Thirty healthy infants who underwent physical examination were enrolled as healthy control group. Fasting venous blood was collected for both groups before and after prednisone treatment. Chemiluminescence was used to measure serum levels of interleukin-1B (IL-1B), interleukin-2R (IL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-α (TNF-α). Immunoturbidimetric assay was used to measure serum levels of immunoglobulin A (IgA), immunoglobulin M (IgM), and immunoglobulin G (IgG). Flow cytometry was used to measure the percentages of T lymphocyte subsets (CD3+, CD4+, and CD8+). The clinical outcome and electroencephalographic findings were evaluated for all IS children after prednisone treatment. Results The IS group had significantly higher serum levels of IL-2R, IL-8, and TNF-α than the healthy control group before treatment (P < 0.05). The mean number of daily ictal clusters was positively correlated with the levels of IL-2R, IL-8, and TNF-α in IS children, the mean number of total daily seizures was positively correlated with IL-8 level, and any two indices out of IL-2R, IL-8, and TNF-α were positively correlated with each other (P < 0.05). Among the 30 IS children treated with prednisone, 19 achieved seizure control; electroencephalography showed that 18 children achieved complete remission of hyperarrhythmia. After treatment, the IS group had significant reductions in the numbers of daily ictal clusters and total daily seizures, significant improvement in developmental quotient (P < 0.05), and significant reductions in serum levels of IL-2R, L-8, and TNF-α, the percentage of CD4+ T lymphocytes, and CD4+/CD8+ ratio (P < 0.05), as well as a significant increase in the percentage of CD8+ T lymphocytes (P < 0.05). Conclusions IS children have immune dysfunction. Prednisone can control seizures in IS children, possibly by regulating and improving immune dysfunction.
CHEN Hui,ZHONG Jian-Min,YI Zhao-Shi et al. Immunological mechanism of prednisone in the treatment of infantile spasm[J]. CJCP, 2017, 19(10): 1044-1050.
CHEN Hui,ZHONG Jian-Min,YI Zhao-Shi et al. Immunological mechanism of prednisone in the treatment of infantile spasm[J]. CJCP, 2017, 19(10): 1044-1050.
Riikonen R. Recent advances in the pharmacotherapy of infantile spasms[J]. CNS Drugs, 2014, 28(4):279-290.
[2]
Pavone P, Striano P, Falsaperla R, et al. Infantile spasms syndrome, West syndrome and related phenotypes:what we know in 2013[J]. Brain Dev, 2014, 36(9):739-751.
O'Callaghan FJ, Edwards SW, Alber FD, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS):a randomised, multicentre, open-label trial[J]. Lancet Neurol, 2017, 16(1):33-42.
[5]
Kuznetsova LV, Vetrilé LA, Karpova MN. Neuroimmunological aspects of the pathogenesis of epilepsy[J]. Usp Fiziol Nauk, 2014, 45(3):3-22.
[6]
Pardo CA, Nabbout R, Galanopoulou AS. Mechanisms of epileptogenesis in pediatric epileptic syndromes:rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES)[J]. Neurotherapeutics, 2014, 11(2):297-310.
[7]
Lux AL. Latest American and European updates on infantile spasms[J]. Curr Neurol Neurosci Rep, 2013, 13(3):334.
[8]
Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days:a multicentre, randomised controlled trial[J]. Lancet, 2004, 364(9447):1773-1778.
[9]
Mohamed BP, Scott RC, Desai N, et al. Seizure outcome in infantile spasms-a retrospective study[J]. Epilepsia, 2011, 52(4):746-752.
Xue J, Qian P, Li H, et al. Atonic elements combined or uncombined with epileptic spasms in infantile spasms[J]. Clin Neurophysiol, 2017, 128(1):220-226.
[12]
Liu ZS, Wang QW, Wang FL, et al. Serum cytokine levels are altered in patients with West syndrome[J]. Brain Dev, 2001, 23(7):548-551.
[13]
Montelli TC, Soares AM, Peraçoli MT. Immunologic aspects of West syndrome and evidence of plasma inhibitory effects on T cell function[J]. Arq Neuropsiquiatr, 2003, 61(3B):731-737.
[14]
Tekgul H, Polat M, Tosun A, et al. Cerebrospinal fluid interleukin-6 levels in patients with West syndrome[J]. Brain Dev, 2006, 28(1):19-23.
[15]
Haginoya K, Noguchi R, Zhao Y, et al. Reduced levels of interleukin-1 receptor antagonist in the cerebrospinal fluid in patients with West syndrome[J]. Epilepsy Res, 2009, 85(2-3):314-317.
Yi ZS, Wu HP, Yu XY, et al. Efficacy and tolerability of high-dose prednisone in Chinese children with infantile spasms[J]. Brain Dev, 2015, 37(1):23-28.
[19]
Villani F, Avanzini G. The use of immunoglobulins in the treatment of human epilepsy[J]. Neurol Sci, 2002, 23 Suppl 1:S33-S37.
[20]
Ohya T, Nagai T, Araki Y, et al. A pilot study on the changes in immunity after ACTH therapy in patients with West syndrome[J]. Brain Dev, 2009, 31(10):739-743.
